Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -21.37% | -8.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.37% | -8.70% | |||
| Cost of Revenue | -63.25% | 576.21% | |||
| Gross Profit | 66.28% | -1,158.99% | |||
| SG&A Expenses | 139.66% | -7.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.07% | -6.17% | |||
| Operating Income | 3.21% | 6.04% | |||
| Income Before Tax | -0.38% | 5.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.38% | 5.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.38% | 5.34% | |||
| EBIT | 3.21% | 6.04% | |||
| EBITDA | 3.02% | 6.48% | |||
| EPS Basic | -0.18% | 5.71% | |||
| Normalized Basic EPS | 3.25% | 5.73% | |||
| EPS Diluted | -0.18% | 5.71% | |||
| Normalized Diluted EPS | 3.25% | 5.73% | |||
| Average Basic Shares Outstanding | 0.21% | 0.40% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||